Patents Assigned to Genzyme Corporation
  • Making a soft tissue prosthesis for repairing a defect of an abdominal wall or a pelvic cavity wall
    Patent number: 8460695
    Abstract: Surgical prostheses and methods of using and making surgical prostheses are disclosed.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: June 11, 2013
    Assignee: Genzyme Corporation
    Inventor: Keith E. Greenawalt
  • AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE
    Publication number: 20130137743
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: November 24, 2010
    Publication date: May 30, 2013
    Applicant: GENZYME CORPORATION
    Inventors: Hanlan Liu, Chris Willis, Renu Bhardwaj, Diane P. Copeland, Abizer Harianawala, Jeffrey Skell, John Marshall, Jianmei Kochling, Gerard Palace, Judith Peterschmitt, Craig Siegel, Seng Cheng
  • Peptide analogs of alpha-melanocyte stimulating hormone
    Patent number: 8440793
    Abstract: Provided herein are stable peptide analogs of the native alpha-melanocyte stimulating hormone (?-MSH) having selectivity for the melanocortin 1 receptor (MC1R). Also provided herein are pharmaceutical preparations of the ?-MSH peptide analogs, as well as methods of using these analogs in the treatment of medical and veterinary conditions involving MC1R.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: May 14, 2013
    Assignee: Genzyme Corporation
    Inventors: Michael A. Perricone, John Lyle Dzuris, Timothy E. Weeden, James E. Stefano, Clark Q. Pan, Andrea E. Edling
  • TREATMENT OF MULTIPLE SCLEROSIS (MS)
    Publication number: 20130108625
    Abstract: A method for treatment of multiple sclerosis (MS) with Campath-1H with significant efficacy and a favourable safety profile is described, which offers an acceptable benefit/risk ratio. Especially described is the use of Campath-1H (alemtuzumab) for the production of a medicament for the treatment of multiple sclerosis (MS), comprising a first treatment cycle followed by at least one further treatment cycle of Campath-1H (alemtuzumab), in which each treatment cycle comprises 1-5 daily doses which are applied on consecutive days, wherein the daily dose is >0 and ?12 mg, and wherein each treatment cycle is separated from the next cycle by at least 1-24 months. Also described are treatment regimens comprising the administration of less than 12 mg/day of Campath-1H for a period of 1-5 consecutive days.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 2, 2013
    Applicants: ALCAFLEU MANAGEMENT GMBH & CO. KG, GENZYME CORPORATION
    Inventors: GENZYME CORPORATION, ALCAFLEU MANAGEMENT GMBH & CO. KG
  • Compositions and methods for detection of lysosomal storage disease
    Patent number: 8431335
    Abstract: The present invention provides compositions for performing assays of enzyme activity associated with lysosomal storage diseases. The invention further provides methods for determining enzyme activity, and methods for the screening for lysosomal storage disease in an individual.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: April 30, 2013
    Assignee: Genzyme Corporation
    Inventors: Xiaokui K. Zhang, Wei-Lien Chuang, Joan Keutzer
  • METHODS OF TREATING PARKINSON'S DISEASE USING VIRAL VECTORS
    Publication number: 20130101510
    Abstract: Methods of delivering viral vectors, particularly recombinant AAV virions, to the CNS are provided. Also provided are methods of treating Parkinson's Disease.
    Type: Application
    Filed: October 8, 2012
    Publication date: April 25, 2013
    Applicants: The Regents of the University of California, Genzyme Corporation
    Inventors: Krys BANKIEWICZ, Janet Cunningham
  • Amide dendrimer compositions
    Patent number: 8425887
    Abstract: Amide compounds, amide polymers, compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, amide compounds and amide polymers may include a core derived from an amide polyol and an organic polyacid or ester.
    Type: Grant
    Filed: September 26, 2007
    Date of Patent: April 23, 2013
    Assignee: Genzyme Corporation
    Inventors: Pradeep K. Dhal, David J. Harris, Stephen Randall Holmes-Farley, Chad C. Huval, Vitaly Nivorozhkin, Bruce Shutts
  • Methods For Increasing Blood Flow And/Or Promoting Tissue Regeneration
    Publication number: 20130095076
    Abstract: Methods for increasing blood flow and/or regenerating tissue using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z???(1).
    Type: Application
    Filed: July 5, 2012
    Publication date: April 18, 2013
    Applicant: Genzyme Corporation
    Inventors: Gary J. BRIDGER, Simon P. FRICKER
  • Method Of Identifying Risk For Thyroid Disorder
    Publication number: 20130095507
    Abstract: A method for identifying a patient that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes lymphocytes, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at increased risk for developing a thyroid disorder. A particular embodiment is a method for identifying a patient with multiple sclerosis that is at risk for developing a thyroid disorder that occurs subsequent to treatment with a regimen that depletes CD52-positive cells, comprising determining whether antibodies directed against thyroid peroxidase or thyroid microsomes are present in the patient, wherein if the antibodies are present in the patient then the patient is at risk for developing the thyroid disorder.
    Type: Application
    Filed: December 5, 2012
    Publication date: April 18, 2013
    Applicant: Genzyme Corporation
    Inventor: Genzyme Corporation
  • Confinement of kidney stone fragments during lithotripsy
    Patent number: 8409218
    Abstract: The present invention improves significantly the success rate of lithotripsy and reduces the risk of tissue damage, by injecting a temporary plug in front, and optionally behind a concretion (for extracorporeal lithotripsy) or behind a concretion (for intracorporeal lithotripsy). One aspect of the present invention relates to injecting an inverse thermosensitive polymer solution into a lumen, thereby preventing the migration of a concretion, or its fragments, upon extracorporeal or intracorporeal lithotripsy.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: April 2, 2013
    Assignee: Genzyme Corporation
    Inventors: Alexander Schwarz, W. Scott McDougal
  • STEPPED CANNULA
    Publication number: 20130079748
    Abstract: Described herein are cannulas having a stepped exterior. Also described are methods of making and using these cannulas, for example to deliver one or more materials to the central nervous system of an animal.
    Type: Application
    Filed: November 16, 2012
    Publication date: March 28, 2013
    Applicants: The Regents of the University of California, Genzyme Corporation, a Sanofi Company
    Inventors: Genzyme Corporation, a Sanofi Company, The Regents of the University of California
  • DEVICE FOR VIRAL INACTIVATION OF LIQUID MEDIA
    Publication number: 20130078702
    Abstract: An apparatus (100) capable of viral inactivation of liquid media includes at least one coaxial cylinder (110) constructed of an outer cylinder (120) and an inner cylinder (130), a liquid media inlet (140), at least one emitter of type C ultraviolet radiation (145), and a liquid media outlet (150). The inner cylinder has an outer diameter adapted to form a gap (160) between the outer diameter of the inner cylinder and the inner diameter of the outer cylinder. The media flows in a substantially cyclonic flow path along the gap. The at least one emitter of type C ultraviolet radiation is placed inside the inner cylinder. The outlet is connected to the outer cylinder at, or proximal to, an end of the outer cylinder opposite the inlet.
    Type: Application
    Filed: June 6, 2011
    Publication date: March 28, 2013
    Applicant: GENZYME CORPORATION
    Inventor: Muthukumar Dhanasekharan
  • DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINOGMYELINASE DEFICIENCY
    Publication number: 20130078230
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Application
    Filed: November 16, 2012
    Publication date: March 28, 2013
    Applicants: Genzyme Corporation, Mount Sinai School of Medicine of New York University
    Inventors: Mount Sinai School of Medicine of New York Unive, Genzyme Corporation
  • DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINOGMYELINASE DEFICIENCY
    Publication number: 20130078231
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Application
    Filed: November 16, 2012
    Publication date: March 28, 2013
    Applicants: Genzyme Corporation, Mount Sinai School of Medicine of New York University
    Inventors: Mount Sinai School of Medicine of New York Unive, Genzyme Corporation
  • Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
    Patent number: 8399657
    Abstract: Methods to introduce highly phosphorylated mannopyranosyl oligosaccharide derivatives containing mannose-6-phosphate (M6P), or other oligosaccharides bearing other terminal hexoses, to carbonyl groups on oxidized glycans of glycoproteins while retaining their biological activity are described. The methods are useful for modifying glycoproteins, including those produced by recombinant protein expression systems, to increase uptake by cell surface receptor-mediated mechanisms, thus improving their therapeutic efficacy in a variety of applications.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: March 19, 2013
    Assignee: Genzyme Corporation
    Inventor: Yunxiang Zhu
  • Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
    Patent number: 8389517
    Abstract: A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: March 5, 2013
    Assignee: Genzyme Corporation
    Inventors: Oxana Ibraghimov-Beskrovnaya, Thomas A. Natoli
  • Antibodies to TGF?
    Patent number: 8383780
    Abstract: The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGF?), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGF?1, TGF?2 and TGF?3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: February 26, 2013
    Assignees: Genzyme Corporation, Optein, Inc.
    Inventors: Steven R. Ledbetter, Celia P. Hart, Robert G. Holgate, Lutz U. Jermutus, Catriona L. Buchanan, Alexander R. Duncan, Donna K. Finch
  • Making a Soft Tissue Prosthesis for Repairing a Defect of an Abdominal Wall or a Pelvic Cavity Wall
    Publication number: 20130045327
    Abstract: Surgical prostheses and methods of using and making surgical prostheses are disclosed.
    Type: Application
    Filed: October 23, 2012
    Publication date: February 21, 2013
    Applicant: GENZYME CORPORATION
    Inventor: Genzyme Corporation
  • Method of drying a material having a cohesive phase
    Patent number: 8378036
    Abstract: A method for drying a material such as a polymer hydrogel which passes through a cohesive phase as it dries is disclosed. The method comprises agitating a composition while removing liquid until the solids content of the composition reaches a level at which the composition enters a cohesive phase, halting agitation, removing liquid from the composition in the absence of agitation, and resuming agitation. Practice of the present invention can eliminate the problems associated with adhesion of a material to itself and to process equipment during the cohesive phase.
    Type: Grant
    Filed: February 27, 2012
    Date of Patent: February 19, 2013
    Assignee: Genzyme Corporation
    Inventor: Gary S. Rea
  • Low salt forms of polyallylamine
    Patent number: 8377428
    Abstract: Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent.
    Type: Grant
    Filed: April 21, 2009
    Date of Patent: February 19, 2013
    Assignee: Genzyme Corporation
    Inventors: John S. Petersen, Steven K. Burke, Stephen Randall Holmes-Farley